Lv25
168 积分 2022-01-22 加入
Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy
1小时前
已完结
Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma
1天前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
2天前
已完结
Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity
3天前
已完结
Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C
6天前
已完结
Discovery of Novel SHP2 ATTEC Degraders against Pancreatic Ductal Adenocarcinoma Harboring KRAS(G12D) Mutations
8天前
已完结
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
9天前
已完结
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
9天前
已完结
Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules
14天前
已完结
RAS-targeted therapies: is the undruggable drugged?
15天前
已完结
皖公网安备34019202002308
